Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

The United States has led the world in pharmaceutical innovation for decades by developing drugs that combat cancer, heart ...

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy ...

Addressing the calculation of patent term extensions (PTEs) under the Hatch-Waxman Act, the US Court of Appeals for the Federal Circuit affirmed ...

For decades, the United States has led the world in pharmaceutical innovation – developing drugs that combat cancer, heart ...

Delhi HC rejects interim injunction plea from Roche against Natco's SMA drug Evrysdi: Our Bureau, New Delhi Thursday, March 27, 2025, 08:00 Hrs [IST] The Delhi High Court has reje ...

Somehow Washington regards the industry, which has saved and improved tens of millions of lives, as a villain.

The FDA should cut off access to these fake and unsafe drugs and allow the normal patent process to work to protect our intellectual property. Patent protection is what has made America the ...

"Several years later, the granting of the patent is getting us closer to ... it must undergo clinical trials, a yearslong process that tests drugs to ensure their safety and efficacy in humans.

If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.